ACTIVATION AND REGULATION OF THE HER2 AND HER4 KINASES

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 信号转导通路的改变在人类肿瘤的生长和转移中起重要作用。我们专注于Her 2/neu受体酪氨酸激酶，EGFR生长因子受体家族的一员，这是基因扩增和激活约25%的人类乳腺癌病例。靶向Her 2/neu的几种药物用于治疗Her 2阳性乳腺癌，例如受体细胞外部分的单克隆抗体或小分子激酶抑制剂，但在患者中经常观察到对这些药物的耐药性。更好地了解Her 2/neu及其下游信号转导通路将为乳腺癌患者提供更好的治疗。 我们的实验室研究乳腺癌的信号转导途径，使用各种方法，涉及生物化学，蛋白质组学和细胞生物学。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Alterations of signal transduction pathways play a significant role in the growth and metastasis of human cancers. We focus on the Her2/neu receptor tyrosine kinase, a member of the EGFR growth factor receptor family, which is gene amplified and activated in about 25% of human breast cancer cases. Several drugs that target Her2/neu are used in the treatment of Her2-positive breast cancer, such as a monoclonal antibody to the extracellular portion of the receptor or small molecule kinase inhibitors, but resistance to these drugs has frequently been seen in patients. Better understanding of Her2/neu and the downstream signal transduction pathways it uses will provide improved treatment for breast cancer patients. Our lab studies signal transduction pathways in breast cancer using a variety of approaches involving biochemistry, proteomics, and cell biology.